We concluded that the effectiveness of first-line therapies in patients with NSCLC may predict survival benefit in the subsequent lines, particularly in EGFR-, ALK-, or PD-L1-positive disease treated by targeted therapies. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.